Ben Uttenthal

442 total citations
8 papers, 102 citations indexed

About

Ben Uttenthal is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Ben Uttenthal has authored 8 papers receiving a total of 102 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pathology and Forensic Medicine, 6 papers in Oncology and 2 papers in Genetics. Recurrent topics in Ben Uttenthal's work include Lymphoma Diagnosis and Treatment (6 papers), Viral-associated cancers and disorders (3 papers) and CAR-T cell therapy research (2 papers). Ben Uttenthal is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Viral-associated cancers and disorders (3 papers) and CAR-T cell therapy research (2 papers). Ben Uttenthal collaborates with scholars based in United Kingdom, Italy and Germany. Ben Uttenthal's co-authors include Robin Sanderson, Andrea Kühnl, Caroline Besley, Maeve O’Reilly, Sunil Iyengar, Claire Roddie, Christopher McNamara, Wendy Osborne, A. V. Hoffbrand and Carol Goulding and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Medical Microbiology.

In The Last Decade

Ben Uttenthal

7 papers receiving 102 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ben Uttenthal United Kingdom	3	73	32	31	18	16	8	102
Sascha Kretschmann Germany	5	79 1.1×	11 0.3×	7 0.2×	25 1.4×	7 0.4×	8	109
Hannah Moatti France	5	59 0.8×	53 1.7×	12 0.4×	37 2.1×	12 0.8×	8	151
Diana Bouhassira United States	4	84 1.2×	10 0.3×	17 0.5×	30 1.7×	8 0.5×	7	125
Caroline Besley United Kingdom	6	109 1.5×	19 0.6×	51 1.6×	27 1.5×	27 1.7×	16	147
Katarzyna Aleksandra Jalowiec Switzerland	7	50 0.7×	38 1.2×	12 0.4×	15 0.8×	10 0.6×	17	146
Harry Miao United States	9	104 1.4×	16 0.5×	64 2.1×	28 1.6×	14 0.9×	33	149
Lester Lledo United States	8	126 1.7×	26 0.8×	21 0.7×	29 1.6×	14 0.9×	8	149
Artur Wilhelm Germany	4	46 0.6×	10 0.3×	9 0.3×	13 0.7×	4 0.3×	4	104
Guido Ghilardi United States	6	36 0.5×	27 0.8×	16 0.5×	47 2.6×	2 0.1×	19	95
Jérôme Paillassa France	6	38 0.5×	35 1.1×	37 1.2×	18 1.0×	8 0.5×	20	78

Countries citing papers authored by Ben Uttenthal

Since Specialization

Citations

This map shows the geographic impact of Ben Uttenthal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ben Uttenthal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ben Uttenthal more than expected).

Fields of papers citing papers by Ben Uttenthal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ben Uttenthal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ben Uttenthal. The network helps show where Ben Uttenthal may publish in the future.

Co-authorship network of co-authors of Ben Uttenthal

This figure shows the co-authorship network connecting the top 25 collaborators of Ben Uttenthal. A scholar is included among the top collaborators of Ben Uttenthal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ben Uttenthal. Ben Uttenthal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Roddie, Claire, Lorna Neill, Wendy Osborne, et al.. (2023). Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Advances. 7(12). 2872–2883. 64 indexed citations

Choquet, Sylvain, Andrew Clark, C. Rénard, et al.. (2023). Effectiveness and safety outcomes in patients with EBV⁺ PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe.. Journal of Clinical Oncology. 41(16_suppl). 7521–7521.

Choquet, Sylvain, Sridhar Chaganti, Ben Uttenthal, et al.. (2022). Demographics and treatment outcomes in patients with EBV⁺ PTLD treated with off-the-shelf EBV-specific CTL under an ongoing expanded access program in Europe: First analyses.. Journal of Clinical Oncology. 40(16_suppl). 7530–7530. 1 indexed citations

O’Reilly, Maeve, Robin Sanderson, William Wilson, et al.. (2022). Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom. Blood. 140(Supplement 1). 7519–7521. 9 indexed citations

Martinelli, Anthony W., Marta S. Lopes, Pramila Krishnamurthy, et al.. (2022). Introducing biomarkers for invasive fungal disease in haemato-oncology patients: a single-centre experience. Journal of Medical Microbiology. 71(7). 1 indexed citations

Fox, Thomas A., Ben Carpenter, Mary Taj, et al.. (2020). Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma. Leukemia & lymphoma. 62(4). 1010–1012. 1 indexed citations

Collins, Anne T., Chandan Saha, Vidyarani Shyamsundar, et al.. (2017). Advanced Hodgkin lymphoma in the east of England cancer network: A 10‐year comparative analysis of outcomes for ABVD and escalated‐BEACOPP treated patients aged 16 to 59. Hematological Oncology. 35(S2). 318–319. 1 indexed citations

Goulding, Carol, Ben Uttenthal, Letizia Foroni, et al.. (2007). The JAK2^V617F tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. International Journal of Laboratory Hematology. 30(5). 415–419. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact